Safety and effectiveness of peficitinib (ASP015K) in patients with rheumatoid arthritis: interim data (22.7 months mean peficitinib treatment) from a long-term, open-label extension study in Japan, Korea, and Taiwan

Safety and effectiveness of peficitinib (ASP015K) in patients with rheumatoid arthritis: interim data (22.7 months mean peficitinib treatment) from a long-term, open-label extension study in Japan, Korea, and Taiwan

Abstract Background Peficitinib (ASP015K), a novel oral Janus kinase inhibitor, has demonstrated efficacy and safety for the treatment of rheumatoid arthritis (RA) in randomized, controlled trials of up to 52 weeks’ duration. However, safety and effectiveness after long-term treatment have not been...

Full description

Bibliographic Details
Main Authors: Tsutomu Takeuchi, Yoshiya Tanaka, Sakae Tanaka, Atsushi Kawakami, Yeong-Wook Song, Yi-Hsing Chen, Mitsuhiro Rokuda, Hiroyuki Izutsu, Satoshi Ushijima, Yuichiro Kaneko, Yoshihiro Nakashima, Teruaki Shiomi, Emi Yamada
Format: Article
Language:English
Published: BMC 2020-03-01
Series:Arthritis Research & Therapy
Subjects:
Rheumatoid arthritis
Janus kinase
Peficitinib
Long-term extension study
ASP015K
Online Access:http://link.springer.com/article/10.1186/s13075-020-2125-2

Internet

http://link.springer.com/article/10.1186/s13075-020-2125-2

Similar Items